-+ 0.00%
-+ 0.00%
-+ 0.00%

CNS Pharmaceuticals Q3 2026 net loss narrows 22% to $2.5 million

PUBT·11/16/2026 12:30:59
Listen to the news
CNS Pharmaceuticals Q3 2026 net loss narrows 22% to $2.5 million
  • CNS Pharmaceuticals’ third-quarter 2026 net loss narrowed 22% year over year to approximately $2.5 million.
  • Research and development expenses fell 59% to approximately $900,000 year over year, primarily due to lower Berubicin clinical and TPI 287 manufacturing costs.
  • General and administrative expenses rose 64% to approximately $1.8 million year over year, primarily due to higher consulting and personnel-related expenses.
  • Cash and cash equivalents more than doubled to approximately $17.2 million at September 30, 2026, compared with December 31, 2025.
  • Advanced acquisition and licensing discussions continue, with the first pipeline-building transaction targeted for completion by year-end 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611160730ACCESSWRNAPR_____1251586) on November 16, 2026, and is solely responsible for the information contained therein.